Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Hongkong, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.99
AMGN's Cash to Debt is ranked lower than
78% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. AMGN: 0.99 )
Ranked among companies with meaningful Cash to Debt only.
AMGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 1.04 Max: 8.25
Current: 0.99
0.32
8.25
Equity to Asset 0.39
AMGN's Equity to Asset is ranked lower than
78% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AMGN: 0.39 )
Ranked among companies with meaningful Equity to Asset only.
AMGN' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.58 Max: 0.84
Current: 0.39
0.34
0.84
Interest Coverage 15.80
AMGN's Interest Coverage is ranked lower than
87% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMGN: 15.80 )
Ranked among companies with meaningful Interest Coverage only.
AMGN' s Interest Coverage Range Over the Past 10 Years
Min: 7.07  Med: 9.53 Max: 48.97
Current: 15.8
7.07
48.97
F-Score: 8
Z-Score: 2.57
M-Score: -2.58
WACC vs ROIC
9.37%
25.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 39.10
AMGN's Operating margin (%) is ranked higher than
94% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. AMGN: 39.10 )
Ranked among companies with meaningful Operating margin (%) only.
AMGN' s Operating margin (%) Range Over the Past 10 Years
Min: 26.91  Med: 31.86 Max: 39
Current: 39.1
26.91
39
Net-margin (%) 32.03
AMGN's Net-margin (%) is ranked higher than
92% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. AMGN: 32.03 )
Ranked among companies with meaningful Net-margin (%) only.
AMGN' s Net-margin (%) Range Over the Past 10 Years
Min: 20.68  Med: 26.36 Max: 31.45
Current: 32.03
20.68
31.45
ROE (%) 25.55
AMGN's ROE (%) is ranked higher than
94% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. AMGN: 25.55 )
Ranked among companies with meaningful ROE (%) only.
AMGN' s ROE (%) Range Over the Past 10 Years
Min: 14.97  Med: 20.52 Max: 24.69
Current: 25.55
14.97
24.69
ROA (%) 9.84
AMGN's ROA (%) is ranked higher than
90% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. AMGN: 9.84 )
Ranked among companies with meaningful ROA (%) only.
AMGN' s ROA (%) Range Over the Past 10 Years
Min: 7.63  Med: 9.30 Max: 12.56
Current: 9.84
7.63
12.56
ROC (Joel Greenblatt) (%) 131.59
AMGN's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. AMGN: 131.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AMGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 61.87  Med: 78.55 Max: 94.49
Current: 131.59
61.87
94.49
Revenue Growth (3Y)(%) 15.10
AMGN's Revenue Growth (3Y)(%) is ranked higher than
73% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. AMGN: 15.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AMGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.9  Med: 15.15 Max: 29.3
Current: 15.1
5.9
29.3
EBITDA Growth (3Y)(%) 19.00
AMGN's EBITDA Growth (3Y)(%) is ranked higher than
76% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. AMGN: 19.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AMGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.1  Med: 14.95 Max: 25.3
Current: 19
1.1
25.3
EPS Growth (3Y)(%) 18.40
AMGN's EPS Growth (3Y)(%) is ranked higher than
76% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. AMGN: 18.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AMGN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 2.3  Med: 16.60 Max: 22.1
Current: 18.4
2.3
22.1
» AMGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

AMGN Guru Trades in Q1 2015

Ray Dalio 4,373 sh (New)
Lee Ainslie 1,570 sh (New)
Joel Greenblatt 309,134 sh (+2874.44%)
Pioneer Investments 37,587 sh (+1331.89%)
Jim Simons 1,524,045 sh (+223.96%)
Paul Tudor Jones 9,865 sh (+114.46%)
Alan Fournier 130,000 sh (+2.36%)
Ken Fisher 156,623 sh (+1.41%)
Mario Gabelli 39,985 sh (+1.23%)
John Buckingham 57,549 sh (+0.79%)
Mairs and Power 10,941 sh (unchged)
Ruane Cunniff 1,617 sh (unchged)
Vanguard Health Care Fund 5,580,485 sh (unchged)
John Hussman Sold Out
PRIMECAP Management 31,488,010 sh (-0.40%)
RS Investment Management 3,790 sh (-5.72%)
Daniel Loeb 10,000,000 sh (-6.32%)
Dodge & Cox 54,704 sh (-17.65%)
First Eagle Investment 497,622 sh (-23.66%)
Jeremy Grantham 499,847 sh (-51.29%)
» More
Q2 2015

AMGN Guru Trades in Q2 2015

Ray Dalio 42,573 sh (+873.54%)
Joel Greenblatt 459,125 sh (+48.52%)
Jeremy Grantham 628,960 sh (+25.83%)
Jim Simons 1,770,245 sh (+16.15%)
Lee Ainslie 1,680 sh (+7.01%)
John Buckingham 58,453 sh (+1.57%)
Alan Fournier 132,000 sh (+1.54%)
Mario Gabelli 40,575 sh (+1.48%)
Vanguard Health Care Fund 5,580,485 sh (unchged)
RS Investment Management 3,790 sh (unchged)
Ruane Cunniff 1,617 sh (unchged)
PRIMECAP Management 31,351,688 sh (-0.43%)
Mairs and Power 10,891 sh (-0.46%)
Ken Fisher 155,101 sh (-0.97%)
Dodge & Cox 50,804 sh (-7.13%)
First Eagle Investment 449,294 sh (-9.71%)
Daniel Loeb 9,000,000 sh (-10.00%)
Paul Tudor Jones 7,975 sh (-19.16%)
Pioneer Investments 2,203 sh (-94.14%)
» More
Q3 2015

AMGN Guru Trades in Q3 2015

John Burbank 20,240 sh (New)
First Pacific Advisors 53,260 sh (New)
Andreas Halvorsen 230,298 sh (New)
John Hussman 40,000 sh (New)
George Soros 2,100 sh (New)
Pioneer Investments 60,111 sh (+2628.60%)
Ray Dalio 62,033 sh (+45.71%)
Ruane Cunniff 2,017 sh (+24.74%)
First Eagle Investment 551,600 sh (+22.77%)
Daniel Loeb 9,850,000 sh (+9.44%)
RS Investment Management 4,097 sh (+8.10%)
Mairs and Power 11,166 sh (+2.53%)
John Buckingham 58,850 sh (+0.68%)
Vanguard Health Care Fund 5,580,485 sh (unchged)
Lee Ainslie 1,680 sh (unchged)
Alan Fournier Sold Out
Mario Gabelli 40,550 sh (-0.06%)
Dodge & Cox 48,344 sh (-4.84%)
PRIMECAP Management 29,175,871 sh (-6.94%)
Jeremy Grantham 579,426 sh (-7.88%)
Joel Greenblatt 406,106 sh (-11.55%)
Jim Simons 1,564,345 sh (-11.63%)
Ken Fisher 133,632 sh (-13.84%)
Paul Tudor Jones 6,800 sh (-14.73%)
» More
Q4 2015

AMGN Guru Trades in Q4 2015

Pioneer Investments 193,844 sh (+222.48%)
First Eagle Investment 957,656 sh (+73.61%)
Ken Fisher 136,400 sh (+2.07%)
PRIMECAP Management 29,177,226 sh (unchged)
Ray Dalio Sold Out
John Buckingham 58,522 sh (-0.56%)
Vanguard Health Care Fund 5,398,985 sh (-3.25%)
Mario Gabelli 39,175 sh (-3.39%)
Dodge & Cox 46,644 sh (-3.52%)
Daniel Loeb 9,042,900 sh (-8.19%)
RS Investment Management 3,758 sh (-8.27%)
Jeremy Grantham 355,863 sh (-38.58%)
Jim Simons 146,500 sh (-90.64%)
John Hussman 900 sh (-97.75%)
» More
» Details

Insider Trades

Latest Guru Trades with AMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Amgen Inc

Vanguard Health Care Fund Comments on Amgen Inc - Mar 27, 2015

We trimmed our position in Amgen (AMGN), a U.S.-based global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. The stock was a strong performer in the latter half of 2014 given restructuring efforts to focus more attention on research and development.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Daniel Loeb Comments on Amgen Inc - Feb 10, 2015

Equity Position: Amgen (AMGN)

Our biggest winner in 2014 was our equity position in the biotechnology company Amgen. In our last letter and at the Robin Hood Investment Conference, we highlighted Amgen as a hidden value situation where investor skepticism in three areas – R&D productivity, operating efficiency, and capital allocation – had obscured the company’s fundamental value.

From our perspective, Amgen’s valuation discount to both biotech peers and even slower- growing pharmaceuticals was unwarranted given Amgen’s compelling mix of long-duration, highly cash-generative mature assets and soon-to-launch blockbuster products. To create shareholder value, we made three specific recommendations: 1) focus the company’s R&D efforts; 2) provide long-term margin guidance demonstrating a commitment to reducing a bloated cost structure; and 3) create clarity on additional shareholder returns.

Apparently, Amgen Chairman and CEO Bob Bradway recognized many of the same sources of investor frustration and he has responded with a company-wide transformation initiative. At Amgen’s Analyst Day in October, Mr. Bradway directly addressed two areas of shareholder skepticism: operating margins and capital allocation. The company shared long-term operating margin and cost reduction targets with investors, noting that 2018 spending will not exceed 2013 levels. This expense discipline should help drive operating margins from 38% to at least 52% over that period. In addition, Amgen guided to a 30% increase in its quarterly dividend and accelerated the resumption of its share repurchase program. The long-term vision and discipline presented at the Analyst Day combined with several subsequent positive clinical pipeline events helped Amgen return nearly 45% to shareholders in 2014, the best performance of all mega cap US healthcare companies and Amgen’s highest annual return since 1999.

Even so, we feel this story is still in its early innings and there is still substantially more value for Amgen shareholders to realize. We believe the company can be more aggressive with its share repurchase program, particularly since the stock remains undervalued at current levels. We also remain focused on Amgen’s R&D productivity, given the company’s disappointing returns on its $30 billion in R&D spending over the past decade. While changes to R&D can take longer to implement, we expect that Mr. Bradway will remain attentive to this area. We hope that the company’s recent immuno-oncology partnership with Kite Pharmaceuticals exemplifies Amgen’s increasing efforts to broaden its R&D capabilities in a financially responsible way. Our work suggests further meaningful opportunities exist to improve and optimize internal processes, particularly around decision-making and project selection. Finally, we believe Amgen should provide more granular detail (e.g., R&D spending by therapeutic area) to investors to provide comfort that its current R&D decisions reflect a careful approach to managing capital.

We look forward to continuing to work with the company and our distinguished Third Point Scientific and Medical Advisory Board Members – Dr. David Agus, Dr. Geoff Ginsburg, and Dr. David Parkinson – to further help tune up a world-class engine of scientific discovery and innovation.

From Daniel Loeb (Trades, Portfolio)’s Third Point Q4 2014 Investor Letter.

Check out Daniel Loeb latest stock trades

Daniel Loeb Comments on Amgen Inc - Oct 22, 2014

Since its founding in 1980, Amgen (AMGN) (“the company”) has been a pioneer in the biotechnology industry, successfully discovering, developing, and marketing therapeutic agents that have meaningfully impacted human health. From 1989 to 2002, Amgen grew five revolutionary biologic drugs into billion dollar blockbuster products in oncology, nephrology, and inflammation. Today, Amgen is a $105 billion market cap company with annual revenues of nearly $20 billion and annual net income e of over $5billion.

Considering this track record, Amgen’s long‐term underperformance relative to its biotech peers is surprising. The company has a compelling mix of long‐duration, high‐margin mature products like Neulasta and Enbrel, and a number of exciting high growth assets, including recently launched blockbusters like Prolia and Xgeva along with innovative late-stage pipeline assets like evolocumab. Yet, using nearly any valuation metric, the Company trades at a substantial discount to peers. Amgen even trades at a discount to the US pharmaceutical sector, despite superior revenue and earnings growth rates. Amgen’s current discount to fair valuation – and the lack of structural hurdles to closing this gap – make it an attractive investment opportunity. Third Point is now one of the company’s largest shareholders.

Amgen has all the hallmarks of a hidden value situation, one of our favorite investment themes. The company does not receive proper credit from investors for either the cash generative potential of its mature products or the coming financial impact of its growth assets. In the mature products segment, we believe revenues will be sustainable and concerns about potential erosion are overstated. With respect to Amgen’s pipeline, we believe the market underappreciates how disruptive some of its new products will be. Our conviction about the company’s growth pipeline has been bolstered by our discussions with Third Point’s newly created Scientific and Medical Advisory Board (“SMAB”) led by renowned oncologist Dr. David Agus. Dr. Agus has helped us assemble a world‐class team of scientists and physicians to assist in our evaluation of therapeutic companies and their clinicalassets.1

We believe the obscured fundamental value and investor skepticism that have led to Amgen’s valuation discount can be easily unlocked. Throughout our due diligence and discussions with sell‐side analysts and other investors, it became clear that the market has penalized Amgen for several key reasons: 1) its historical lack of R&D productivity; 2) more than a decade of flat operating margins; and 3) the suspension of its share repurchase program in 2013 following its $9 billion acquisition of Onyx Pharmaceuticals.

First, on R&D productivity, our analyses confirm that Amgen’s R&D efforts have been more costly and less efficient than those of its biotech peers. Despite investing a cumulative $32 billion in R&D since 2002, over 75% of Amgen’s current revenues still come from products introduced before that year. Amgen also appears to spend significantly more money on its late‐stage pipeline assets than any of its biotech peers – both in absolute terms and relative to the number of development projects. Given this sparse output versus to investment, we believe improvements are needed in Amgen’s R&D evaluation process, a hypothesis supported by members of our SMAB.

Second, the market has rightfully punished Amgen for having flat operating margins since 2002 despite a 3x increase in revenues, a failure we attribute to excessive spending. For starters, the bloated cost structure is troubling given that Amgen competes in specialized therapeutic areas which require small, highly focused sales and marketing efforts, and generates the majority of its revenues from just a few well‐established, popular drugs. Another puzzle is that while the biotechnology industry has seen substantial improvements in manufacturing efficiency, Amgen has not demonstrated any of the obvious economies of scale (e.g., procurement, sourcing) that should have been realized. Against this backdrop, the company’s lack of operating margin leverage over this period is doubly surprising. Given its revenue growth, we are convinced that Amgen should have seen meaningful operating margin expansion since 2002, a shortcoming which we believe management has now acknowledged. We believe recent efforts to trim costs do not even scratch the potential opportunity.

Third, in 2013, Amgen’s management made a questionable capital allocation decision: the company purchased Onyx Pharmaceuticals at a 40%+ premium for $9 billion in cash while halting its own share repurchase program. At the time, the company said that its buyback would remain halted until 2016. Based on corporate filings, during the deal negotiations, Amgen had concerns about Onyx’s lead compound, Kyprolis, and renegotiated to reduce the price. Since the acquisition closed, Amgen has disclosed that while the ASPIRE trial for Kyprolis met its clinical endpoints, its sister FOCUS trial failed to show clinical benefit and introduced potential concerns over renal‐adverse events. Instead of the Onyx purchase, Amgen could have accretively repurchased over 10% of its shares outstanding, at the depressed valuation of just 4x sales. Beyond Onyx, we question whether the return on Amgen’s $17 billion in M&A spending since 2002 (on top of the aforementioned $32 billion in R&D spending) has been economically justified, both in absolute terms and also relative to other transactions in the sector. We are challenged to identify any “home‐run” acquisitions and, while still early, believe that most of these transactions will turn out to show mediocre returns.

We believe that Amgen management can directly address all three sources of legitimate investor frustration and, based on our discussions to date with management, we believe that they will. While we applauded Amgen’s first steps in July to target the company’s inflated cost structure by rationalizing its US facilities footprint and creating centers of R&D excellence in San Francisco and Boston, we believe much more can and should be done. Immediate actions Amgen can take to create shareholder value include: 1) Focusing its R&D efforts; 2) Providing long‐term margin guidance demonstrating a commitment to reducing a bloated cost structure; and 3) Creating clarity on additional shareholder returns.

We have also asked the company to seriously consider a more radical option, one first proposed by Geoffrey Porges at Sanford Bernstein. It is well‐established that disparate business units generally benefit from operating separately due to distinct corporate cultures, superior efficiencies, and a greater focus for employees and management alike. Given the diverse nature of its assets – cash‐generative Mature Products and R&D‐intensive Growth Products – we believe that Amgen could benefit from a separation into distinct operating units with separate financial statements and should seriously consider separating into two companies (e.g., a MatureCo and a GrowthCo). Internally, each business would have different priorities: MatureCo would focus on efficiency and cashflow, while GrowthCo would emphasize product development and innovation. Externally, each business would be valued with different metrics: MatureCo on a dividend yield and GrowthCo on a peer‐based sales or earnings multiple. Our own extensive diligence suggests that a break‐up of Amgen is feasible and that purported constraints such as tax strategy and supply chain management can be managed.

A separation of Amgen into MatureCo and GrowthCo would likely be very well received by investors. We expect that MatureCo would receive a valuation based on its dividend yield while GrowthCo would be valued, like peers, on a high growth multiple on earnings, reflective of the burgeoning pipeline. Importantly, however, we believe that a separation would not just be good for shareholders, but that it is a more effective way of running each business. In particular, we believe that the benefits to GrowthCo would be the most meaningful: talent retention, more rapid decision making, and ultimately, accelerated development of new therapies to improve countless lives. We urge Amgen management and a committee of independent directors to conduct their own in‐depth evaluation of this strategic option and share their findings with investors.

We believe there are three ways to win in Amgen, depending on the path management takes from here. If Amgen is simply valued at one turn below its pharmaceutical peers at 17x earnings – a change we expect to be driven by management’s current restructuring plans – the stock should be worth $189 per share by the end of 2016. If Amgen fully seizes the opportunities outlined in our recommendations to focus its R&D, announce structural expense reductions, and accelerate capital deployment, we believe 2017 EPS will reach $12.82 (versus consensus of $11.12 currently), implying a share price of $218 on the same multiple. We see the most upside, however, in the scenario where Amgen strategically separates into two standalone business, as we have encouraged management to consider. In two years, we expect that such a separation could create almost $249 per share in total value, over 80% upside to the current share price.

CEO Bob Bradway and his team have been open‐minded and receptive to our ideas to date and we firmly believe that the company is at an inflection point. The company’s upcoming Analyst Day presents an excellent chance for Amgen management to take bold action and provide clear direction for the company, its investors, and its employees. We hope to maintain our constructive dialogue with management as the company moves towards closing its valuation gap.

From Daniel Loeb (Trades, Portfolio)’s Third Point Q3 2014 Investor Letter.

Check out Daniel Loeb latest stock trades

Top Ranked Articles about Amgen Inc

Loeb, Ackman's Portfolios Post Losses for Year as Top Bets Fall Drug company stocks pulled back on drug price increase concerns
During a volatile market during the third quarter, several prominent hedge funds saw their returns decline. Read more...
PRIMECAP Sells Portions of Its Top Two Stakes
Pasadena, California-based PRIMECAP Management (Trades, Portfolio) was founded in September 1983 as an independent investment management company. It evaluates securities based on their outlook over three to five years, longer if warranted. The Vanguard PRIMECAP Fund, one of the funds it manages, logged a return of 18.72% in 2014. Read more...
Vanguard Health Care Fund Comments on Amgen Inc
We trimmed our position in Amgen (AMGN), a U.S.-based global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. The stock was a strong performer in the latter half of 2014 given restructuring efforts to focus more attention on research and development. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 17.28
AMGN's P/E(ttm) is ranked higher than
77% of the 390 Companies
in the Global Biotechnology industry.

( Industry Median: 26.50 vs. AMGN: 17.28 )
Ranked among companies with meaningful P/E(ttm) only.
AMGN' s P/E(ttm) Range Over the Past 10 Years
Min: 10.4  Med: 17.29 Max: 37.29
Current: 17.28
10.4
37.29
Forward P/E 11.81
AMGN's Forward P/E is ranked higher than
70% of the 341 Companies
in the Global Biotechnology industry.

( Industry Median: 16.50 vs. AMGN: 11.81 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 17.28
AMGN's PE(NRI) is ranked higher than
75% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 30.72 vs. AMGN: 17.28 )
Ranked among companies with meaningful PE(NRI) only.
AMGN' s PE(NRI) Range Over the Past 10 Years
Min: 10.4  Med: 17.31 Max: 37.39
Current: 17.28
10.4
37.39
P/B 3.90
AMGN's P/B is ranked lower than
69% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. AMGN: 3.90 )
Ranked among companies with meaningful P/B only.
AMGN' s P/B Range Over the Past 10 Years
Min: 1.8  Med: 3.56 Max: 5.21
Current: 3.9
1.8
5.21
P/S 5.18
AMGN's P/S is ranked higher than
67% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.77 vs. AMGN: 5.18 )
Ranked among companies with meaningful P/S only.
AMGN' s P/S Range Over the Past 10 Years
Min: 4.05  Med: 5.81 Max: 12.04
Current: 5.18
4.05
12.04
PFCF 12.83
AMGN's PFCF is ranked higher than
77% of the 269 Companies
in the Global Biotechnology industry.

( Industry Median: 27.55 vs. AMGN: 12.83 )
Ranked among companies with meaningful PFCF only.
AMGN' s PFCF Range Over the Past 10 Years
Min: 8.78  Med: 13.80 Max: 29.89
Current: 12.83
8.78
29.89
POCF 11.71
AMGN's POCF is ranked higher than
79% of the 395 Companies
in the Global Biotechnology industry.

( Industry Median: 27.92 vs. AMGN: 11.71 )
Ranked among companies with meaningful POCF only.
AMGN' s POCF Range Over the Past 10 Years
Min: 7.24  Med: 12.23 Max: 23.4
Current: 11.71
7.24
23.4
EV-to-EBIT 16.82
AMGN's EV-to-EBIT is ranked higher than
58% of the 452 Companies
in the Global Biotechnology industry.

( Industry Median: 18.07 vs. AMGN: 16.82 )
Ranked among companies with meaningful EV-to-EBIT only.
AMGN' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.3  Med: 18.10 Max: 34.6
Current: 16.82
9.3
34.6
EV-to-EBITDA 13.55
AMGN's EV-to-EBITDA is ranked higher than
60% of the 479 Companies
in the Global Biotechnology industry.

( Industry Median: 15.17 vs. AMGN: 13.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.9  Med: 14.70 Max: 28.7
Current: 13.55
7.9
28.7
PEG 1.66
AMGN's PEG is ranked higher than
63% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. AMGN: 1.66 )
Ranked among companies with meaningful PEG only.
AMGN' s PEG Range Over the Past 10 Years
Min: 0.23  Med: 1.25 Max: 2.57
Current: 1.66
0.23
2.57
Shiller P/E 28.05
AMGN's Shiller P/E is ranked higher than
81% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 47.95 vs. AMGN: 28.05 )
Ranked among companies with meaningful Shiller P/E only.
AMGN' s Shiller P/E Range Over the Past 10 Years
Min: 17.42  Med: 27.17 Max: 65.71
Current: 28.05
17.42
65.71
Current Ratio 5.42
AMGN's Current Ratio is ranked higher than
55% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. AMGN: 5.42 )
Ranked among companies with meaningful Current Ratio only.
AMGN' s Current Ratio Range Over the Past 10 Years
Min: 1.31  Med: 3.15 Max: 6.33
Current: 5.42
1.31
6.33
Quick Ratio 5.07
AMGN's Quick Ratio is ranked higher than
55% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. AMGN: 5.07 )
Ranked among companies with meaningful Quick Ratio only.
AMGN' s Quick Ratio Range Over the Past 10 Years
Min: 1.17  Med: 2.75 Max: 5.75
Current: 5.07
1.17
5.75
Days Inventory 222.19
AMGN's Days Inventory is ranked lower than
74% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. AMGN: 222.19 )
Ranked among companies with meaningful Days Inventory only.
AMGN' s Days Inventory Range Over the Past 10 Years
Min: 188.11  Med: 306.29 Max: 374.86
Current: 222.19
188.11
374.86
Days Sales Outstanding 50.47
AMGN's Days Sales Outstanding is ranked higher than
64% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. AMGN: 50.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.32  Med: 52.64 Max: 67.84
Current: 50.47
46.32
67.84
Days Payable 92.14
AMGN's Days Payable is ranked higher than
66% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. AMGN: 92.14 )
Ranked among companies with meaningful Days Payable only.
AMGN' s Days Payable Range Over the Past 10 Years
Min: 54.15  Med: 98.37 Max: 117.72
Current: 92.14
54.15
117.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.33
AMGN's Dividend Yield is ranked higher than
87% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 1.31 vs. AMGN: 2.33 )
Ranked among companies with meaningful Dividend Yield only.
AMGN' s Dividend Yield Range Over the Past 10 Years
Min: 0.48  Med: 1.60 Max: 2.34
Current: 2.33
0.48
2.34
Dividend Payout 0.36
AMGN's Dividend Payout is ranked higher than
98% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. AMGN: 0.36 )
Ranked among companies with meaningful Dividend Payout only.
AMGN' s Dividend Payout Range Over the Past 10 Years
Min: 0.22  Med: 0.32 Max: 0.56
Current: 0.36
0.22
0.56
Dividend Growth (3y) 63.30
AMGN's Dividend Growth (3y) is ranked higher than
92% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. AMGN: 63.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
AMGN' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 63.3
Current: 63.3
0
63.3
Forward Dividend Yield 2.76
AMGN's Forward Dividend Yield is ranked higher than
81% of the 217 Companies
in the Global Biotechnology industry.

( Industry Median: 1.33 vs. AMGN: 2.76 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.34
AMGN's Yield on cost (5-Year) is ranked higher than
76% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 1.55 vs. AMGN: 2.34 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
AMGN' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.48  Med: 1.60 Max: 2.34
Current: 2.34
0.48
2.34
3-Year Average Share Buyback Ratio 5.50
AMGN's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: -9.90 vs. AMGN: 5.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.5  Med: 4.45 Max: 8.3
Current: 5.5
-7.5
8.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 66.08
AMGN's Price/Tangible Book is ranked lower than
98% of the 1047 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. AMGN: 66.08 )
Ranked among companies with meaningful Price/Tangible Book only.
AMGN' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.67  Med: 13.50 Max: 150.51
Current: 66.08
4.67
150.51
Price/Projected FCF 1.38
AMGN's Price/Projected FCF is ranked higher than
89% of the 283 Companies
in the Global Biotechnology industry.

( Industry Median: 2.87 vs. AMGN: 1.38 )
Ranked among companies with meaningful Price/Projected FCF only.
AMGN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.59  Med: 1.17 Max: 6.23
Current: 1.38
0.59
6.23
Price/DCF (Earnings Based) 0.98
AMGN's Price/DCF (Earnings Based) is ranked higher than
65% of the 37 Companies
in the Global Biotechnology industry.

( Industry Median: 2.12 vs. AMGN: 0.98 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.18
AMGN's Price/Median PS Value is ranked lower than
69% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. AMGN: 1.18 )
Ranked among companies with meaningful Price/Median PS Value only.
AMGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.72  Med: 1.45 Max: 5.19
Current: 1.18
0.72
5.19
Price/Peter Lynch Fair Value 1.15
AMGN's Price/Peter Lynch Fair Value is ranked higher than
66% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 1.73 vs. AMGN: 1.15 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
AMGN' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.58  Med: 1.54 Max: 3.34
Current: 1.15
0.58
3.34
Price/Graham Number 7.96
AMGN's Price/Graham Number is ranked lower than
87% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 3.04 vs. AMGN: 7.96 )
Ranked among companies with meaningful Price/Graham Number only.
AMGN' s Price/Graham Number Range Over the Past 10 Years
Min: 1.52  Med: 4.07 Max: 11.67
Current: 7.96
1.52
11.67
Earnings Yield (Greenblatt) (%) 5.91
AMGN's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. AMGN: 5.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.9  Med: 5.50 Max: 10.8
Current: 5.91
2.9
10.8
Forward Rate of Return (Yacktman) (%) 20.32
AMGN's Forward Rate of Return (Yacktman) (%) is ranked higher than
64% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. AMGN: 20.32 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AMGN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.9  Med: 15.40 Max: 71.3
Current: 20.32
1.9
71.3

More Statistics

Revenue(Mil) $21662
EPS $ 9.07
Beta1.34
Short Percentage of Float1.57%
52-Week Range $130.09 - 181.81
Shares Outstanding(Mil)754.33

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 22,357 24,029 24,901
EPS($) 10.80 12.26 13.34
EPS without NRI($) 10.80 12.26 13.34

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, GILD, BIIB, CELG, CMXHY » details
Traded in other countries:AMGN.Argentina, AMGN34.Brazil, AMGN.Chile, AMG.Germany, 04332.Hongkong, AMG N.Mexico, AMGN.Switzerland, 0R0T.UK,
Amgen Inc was incorporated in the State of Delaware on October 31, 1986. It is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics. Its Cardiovascular products include Repatha, Corlanor, Inflammation products include Brodalumab, Nephrology, Oncology products include BLINCYTO, Kyprolis, Neulasta, Rilotumumab, Talimogene laherparepvec, Trebananib, Biosimilars, among others. Its geographic areas of operations include USA, Europe and Canada. Certain raw materials, medical devices and components necessary for the commercial and/or clinical manufacturing of the Company's products are provided by and are the proprietary products of unaffiliated third-party suppliers, certain of which may be its only sources for such materials. The Company's sales and marketing forces are mainly located in the United States and Europe. Together with its partners, the Company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals and pharmacies. In the United States, the Company sells primarily to pharmaceutical wholesale distributors. The Company's competitors include Teva Pharmaceutical Industries Ltd., Janssen Biotech, Inc., AbbVie Inc., Merck & Company, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Eli Lilly/Bristol-Myers Squibb Company, Merck KGaA, Genentech, Inc., GlaxoSmithKline PLC, Millennium Pharmaceuticals, Inc., and Celgene Corporation. Some of the Company's patents include Neulasta, NEUPOGEN, Enbrel, XGEVA, Prolia, EPOGEN, Aranesp, Sensipar, Mimpara, Kyprolis, Nplate, Vectibix, and BLINCYTO. The Company's business has been and will continue to be subject to various other U.S. and foreign laws, rules and/or regulations.
» More Articles for AMGN

Headlines

Articles On GuruFocus.com
Gilead, Johnson & Johnson or Roche? Feb 11 2016 
Plenty of Opportunity to Buy Individual Stocks: John Buckingham Feb 02 2016 
Alan Fournier Sells GM, Buys Molson Coors Brewing Jan 03 2016 
Analyzing Amgen's Dividend Hike Dec 20 2015 
Allergan Among Health Care Holdings in Alan Fournier's Portfolio Dec 15 2015 
PRIMECAP Sells Stake in Technology Company Nov 16 2015 
Loeb, Ackman's Portfolios Post Losses for Year as Top Bets Fall Oct 16 2015 
10 Best Stocks for Value Investors This Week - Sept. 26 Sep 26 2015 
Activist Hedge Fund Manager Dan Loeb Decreases Position in Leading Biotech Company Sep 24 2015 
The Best Companies of the Pharmaceuticals Industry – August 2015 Aug 18 2015 

More From Other Websites
Express Scripts sees slow 2016 sales for new cholesterol drugs Feb 12 2016
Morgan Stanley is Wrong: This Biotech is Ready to Explode Higher Feb 11 2016
Amgen, Celgene Buck Short Interest Trend In Biotech Stocks Feb 11 2016
19 Stocks You Should Own if the U.S. Falls Into a Recession Feb 11 2016
EU agency accepts Sandoz application for pegfilgrastim biosimilar Feb 11 2016
Novartis And the Future Of Drug Pricing Feb 10 2016
Relypsa: This Biotech Just Released Stunning Data Feb 10 2016
Panel Recommends FDA Approval of Remicade Knockoff Feb 10 2016
Major Biotech Short Interest Continues to Be Mixed Feb 10 2016
Panel Recommends FDA Approval of Remicade Knockoff Feb 10 2016
A new drug that could save the US billions of dollars just got one step closer to approval Feb 09 2016
Biotech ETFs Slide as Stocks Report Mixed Q4 Results Feb 09 2016
What Investors Can Expect from Healthcare Sector Companies Feb 09 2016
#1 Rated Biotech Analyst on the Sell-Off Feb 08 2016
3 Biotech Stocks to Turn the Tide This Earnings Season Feb 08 2016
Avoid biotech until elections? Analyst's view Feb 08 2016
Regeneron: It's the Eylea Outlook That Matters Feb 08 2016
UK cost agency rebuffs Sanofi cholesterol drug but backs Amgen's Feb 08 2016
UK cost agency rebuffs Sanofi cholesterol drug but backs Amgen's Feb 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK